Abnormal indices of autonomic function are no longer predictors of poor outcome in diabetic patients without neuropathy but with coexisting coronary artery disease who receive optimal pharmacological therapy

Kardiologia Polska

Volumn 67, Issue 12, 2009, Pages 1325-1332

  Ponikowska, Beata ^a   Jankowska, Ewa A ^a,b   Reczuch, Krzysztof ^a,b   Wȩgrzynowska Teodorczyk, Kinga ^b   Witkowski, Tomasz ^b   Rydlewska, Agnieszka ^b   Borodulin Nadzieja, Ludmiła ^a   Banasiak, Waldemar ^b   Francis, Darrel ^c   Ponikowski, Piotr ^a,b  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

^b MILITARY HOSPITAL   (Poland)

^c ST MARY S HOSPITAL   (United Kingdom)

Author keywords

Autonomic balance; Baroreceptor sensitivity; Coronary artery disease; Diabetes mellitus; Prognosis

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; METFORMIN; SULFONYLUREA;

ADULT; ARTICLE; AUTONOMIC NERVOUS SYSTEM; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIABETIC PATIENT; FEMALE; FOLLOW UP; HEART RATE VARIABILITY; HOSPITAL ADMISSION; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; NEUROPATHY; PRESSORECEPTOR REFLEX; PROGNOSIS;

EID: 74549224544     PISSN: 00229032     EISSN: 00229032     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Andrew JM, Boulton AJM, Vinik AI, et al. Diabetic Neuropathies: A statement by the American Diabetes Association. Diabetes Care 2005; 28: 956-62.
2. Vinik AI, Ziegler D. Diabetic cardiovascular autonomic neuropathy. Circulation 2007; 115: 387-97.
3. Maser RE, Mitchell BD, Vinik AI, et al. The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta-analysis. Diabetes Care 2003; 6: 1895-901.
4. American Diabetes Association and American Academy of Neurology: proceedings of a consensus development conference on standardized measures in diabetic neuropathy. Diabetes Care 1992; 15: 1080-107.
5. Task Force of the European Society of Cardiology and the North American Society of pacing. Heart rate variability. Standards of measurement, physiological interpretation, and clinical use. Circulation 1996; 93: 1043-65.
6. Lombardi F, Malliani A, Pagani M, et al. Heart rate variability and its sympatho-vagal modulation. Cardiovasc Res 1996; 32: 208-16.
7. Lanfranchi PA, Somers VK. Arterial baroreflex function and cardiovascular variability: interactions and implications. Am J Physiol Regul Integr Comp Physiol 2002; 283: R815-26.
8. James MA, Panerai RB, Potter JF. Applicability of new techniques in the assessment of arterial baroreflex sensitivity in the elderly: a comparison with established pharmacological methods. Clin Sci (Lond) 1998; 94: 245-53.
9. Eberly LE, Cohen JD, Prineas R, et al. Impact of incident diabetes and incident nonfatal cardiovascular disease on 18-year mortality: the multiple risk factor intervention trial experience. Diabetes Care 2003; 26: 848-54.
10. Schramm TK, Gislason GH, Køber L, et al. Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3.3 million people. Circulation 2008; 117: 1945-54.
11. Bigger JT Jr, Fleiss JT, Steinman RC, et al. Frequency domain measures of heart period variability and mortality after myocardial infarction. Circulation 1992; 85: 164-71.
12. Ponikowski P, Anker SD, Chua TP, et al. Depressed heart rate variability as an independent predictor of death in chronic congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1997; 79: 1645-50.
13. La Rovere MT, Bigger Jr JT, Marcus FI, et al. Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction. Lancet 1998; 351: 478-84.
14. Rydén L, Standl E, Bartnik M, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007; 28: 88-136.
15. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2003; 26: S5-20.
16. Witkowski T, Jankowska EA, Ponikowska B, et al. Zastosowanie nieinwazyjnych metod oceny odruchu z baroreceptorów tȩtniczych u pacjentów z chorobami układu kra̧żenia. Pol Przegla̧d Kardiologiczny 2004; 6: 159-65.
17. Colhoun HM, Francis DP, Rubens MB, et al. The association of heart-rate variability with cardiovascular risk factors and coronary artery calcification: a study in type 1 diabetic patients and the general population. Diabetes Care 2001; 24: 1108-14.
18. Pitzalis MV, Mastropasqua F, Passantino A, et al. Comparison between noninvasive indices of baroreceptor sensitivity and the phenylephrine method in post-myocardial infarction patients. Circulation 1998; 97: 1362-7.
19. Davies LC, Francis DP, Scott AC, et al. Effect of altering conditions of the sequence method on baroreflex sensitivity. J Hypertens 2001; 19: 1279-87.
20. Davies L C, Colhoun H, Coats AJ, et al. A noninvasive measure of baroreflex sensitivity without blood pressure measurement. Am Heart J 2002; 143: 441-7.
21. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-70.
22. Ewing DJ, Martyn CN, Young RJ, et al. The value of cardiovascular autonomic tests: 10 years' experience in diabetes. Diabetes Care 1985; 8: 491-8.
23. Mésangeau D, Laude D, Elghozi JL. Early detection of cardiovascular autonomic neuropathy in diabetic pigs using blood pressure and heart rate variability. Cardiovasc Res 2000; 45: 889-99.
24. Goraya TY, Leibson CL, Palumbo PJ, et al. Coronary atherosclerosis in diabetes mellitus: a population-based autopsy study. J Am Coll Cardiol 2002; 40: 946-53.
25. Donahoe SM, Stewart GC, McCabe CH, et al. Diabetes and mortality following acute coronary syndromes. JAMA 2007; 298: 765-75.
26. Stirban AO, Tschoepe D. Cardiovascular complications in diabetes: targets and interventions. Diabetes Care 2008; 31 (Suppl. 2): S215-21.
27. Mortara A, La Rovere MT, Pinna GD, et al. Nonselective beta-adrenergic blocking agent, carvedilol, improves arterial baroflex gain and heart rate variability in patients with stable chronic heart failure. J Am Coll Cardiol 2000; 36: 1612-8.
28. Ebbehoj E, Poulsen PL, Hansen KW, et al: Effects on heart rate variability of metoprolol supplementary to on going ACE-inhibitor treatment in type I diabetic patients with abnormal albuminuria. Diabetologia 2002; 45: 965-75.
29. Kontopoulos AG, Athyros VG, Didangelos TP, et al. Effect of chronic quinapril administration on heart rate variability in patients with diabetic autonomic neuropathy. Diabetes Care 1997; 20: 355-61.
30. Maser RE, Lenhard MJ. Effect of treatment with losartan on cardiovascular autonomic and large sensory nerve fiber function in individuals with diabetes mellitus: a 1-year randomized, controlled trial. J Diabetes Complications 2003; 17: 286-91.
31. Szramka M, Harriss L, Ninnio D, et al. The effect of rapid lipid lowering with atorvastatin on autonomic parameters in patients with coronary artery disease. Int J Cardiol 2007; 117: 287-91.
32. Huelsmann M, Neuhold S, Strunk G, et al. NT-proBNP has a high negative predictive value to rule-out short-term cardiovascular events in patients with diabetes mellitus. Eur Heart J 2008; 29: 2259-64.
33. Tarnow L, Gall MA, Hansen BV, et al. Plasma N-terminal pro-B-type natriuretic peptide and mortality in type 2 diabetes. Diabetologia 2006; 49: 2256-62.
34. Natarajan S, Liao Y, Cao G, et al. Sex differences in risk for coronary heart disease mortality associated with diabetes and established coronary heart disease. Arch Intern Med 2003; 163: 1735-40.